Bristol Myers CEO stays bullish on Cobenfy despite trial flop, signs of slowing momentum
Cobenfy, the novel antipsychotic drug that Bristol Myers Squibb obtained from a $14 billion acquisition, could have a problem following a phase 3 flop and "moderating" new-to-brand prescription growth. But the company's top executives don't see things that way.
Cobenfy, the novel antipsychotic drug that Bristol Myers Squibb obtained from a $14 billion acquisition, could have a problem following a phase 3 flop and "moderating" new-to-brand prescription growth. But the company's top executives don't see things that way.
